Fractionated administration of irinotecan and cisplatin for treatment of lung cancer: a phase I study

1999

Using Irinotecan and Cisplatin to Treat Lung Cancer

Sample size: 24 publication Evidence: moderate

Author Information

Author(s): Ueoka H, Tabata M, Kiura K, Shibayama T, Gemba K, Segawa Y, Chikamori K, Yonei T, Hiraki S, Harada M

Primary Institution: Okayama University Medical School

Can fractionated administration of irinotecan and cisplatin improve treatment outcomes for lung cancer patients?

The study found that the combination of irinotecan and cisplatin is feasible and shows promising response rates in lung cancer treatment.

The objective response rates were 76% for non-small-cell lung cancer and 100% for small-cell lung cancer.
Diarrhoea was identified as a dose-limiting toxicity.

Doctors tested a new way to give two cancer medicines to help people with lung cancer, and it worked well for many of them.

Patients received fixed doses of cisplatin and escalating doses of irinotecan every four weeks.

The study was limited by the occurrence of severe toxicities in some patients.

Participants were previously untreated patients with unresectable non-small-cell lung cancer or extensive small-cell lung cancer.

Access the complete publication on the publisher's website